In light of the CD8 dependence of TRMN-elicited tumor immunity in the context of lack of activity of CD8+ T cells from TRMN-immunized mice in vitro in ELISpot and cytotoxicity assays, the activity of TRMN-elicited CD8+ T cells was tested in vivo in an adoptive transfer assay. The gene discussed is CD8A; the disease is neoplasm.